NCT01847664

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

A Randomised, Double-blind, Double-dummy, Multi-centre, Comparative Parallel-group Study to Evaluate the Efficacy of Oral Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in the Treatment of Acute Uncomplicated Diverticulitis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 204 (actual)
• Sponsor: Dr. Falk Pharma GmbH · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the trial is to compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo in patients with acute uncomplicated diverticulitis.

Conditions

• Uncomplicated Diverticulitis

Interventions

Type	Name	Description
DRUG	Rifamycin SV-MMX® 400 mg b.i.d.
DRUG	Rifamycin SV-MMX® 600 mg t.i.d.
DRUG	Rifamycin SV-MMX® Placebo

Timeline

• Start date: 2013-08-01
• Primary completion: 2017-07-01
• Completion: 2017-07-01
• First posted: 2013-05-07
• Last updated: 2017-07-26

Locations

1 site across 1 country: Germany